EP Patent

EP2253318A1 — Improvement of dissolvability of preparation containing olmesartan medoxomil

Assigned to Daiichi Sankyo Co Ltd · Expires 2010-11-24 · 15y expired

What this patent protects

Disclosed is a pharmaceutical composition containing olmesartan medoxomil and amlodipine, which has improved dissolvability. The pharmaceutical composition contains (A) olmesartan medoxomil, (B) amlodipine and (C) a calcium-containing additive.

USPTO Abstract

Disclosed is a pharmaceutical composition containing olmesartan medoxomil and amlodipine, which has improved dissolvability. The pharmaceutical composition contains (A) olmesartan medoxomil, (B) amlodipine and (C) a calcium-containing additive.

Drugs covered by this patent

Patent Metadata

Patent number
EP2253318A1
Jurisdiction
EP
Classification
—
Expires
2010-11-24
Drug substance claim
No
Drug product claim
No
Assignee
Daiichi Sankyo Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.